SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending following news of a $400 million AI partnership with Perplexity, combined with a $500 million stock buyback program and positive Q3 earnings results. The community is discussing whether this marks a true turnaround for the stock, with some anticipating a short squeeze while others remain skeptical of the company's long-term profitability.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is trending downwards, with community members expressing concerns about recent performance despite a reported earnings beat. Discussions center around a distributor termination charge impacting EPS, as well as potential channel stuffing and inventory issues. Some investors view the dip as a buying opportunity, citing long-term growth potential and Pepsi's increased involvement, while others are losing faith.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending amid a new partnership with ESPN, but community reactions are mixed, with some questioning the deal's impact and others hoping it will boost market share against competitors like FanDuel. Some traders are pointing to short squeeze potential, while others express concerns about upcoming earnings and competition from prediction markets. Community members are actively debating the financial implications of the ESPN deal and whether it will translate to long-term growth.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending due to investor frustration after earnings, with the community expressing disappointment over a lack of new partnerships and concerns about the CEO's strategy, especially regarding the CIC/Flu program. Many feel the company isn't prioritizing shareholder value, while others suggest a potential acquisition could be the best path forward amid skepticism about current management and execution.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix's stock is trending downwards as investors express frustration and distrust in management following repeated delays and missed deadlines, specifically regarding commercial smartphone production. The community is actively discussing the company's 2026 outlook, potential acquisitions, and the likelihood of securing purchase orders, with some expressing concern that competitors may catch up due to the delays, while others await CES for updates on smart eyewear products.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo's stock is experiencing volatility amid discussions around its growth prospects and potential competition from AI-powered language learning tools. While some traders are betting on a rebound, others express concern about the company's valuation and future performance. Community members are actively debating the impact of AI on Duolingo's business model, with some suggesting AI could enhance its offerings.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's stock is trending as investors digest its latest earnings report, with some analysts raising price targets. Despite the positive outlook, the stock is experiencing volatility as the community debates whether the current valuation is justified and anticipates potential upgrades. Discussions also include the impact of prediction markets and potential partnerships.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending amid community excitement over the company's progress and potential profitability, with many highlighting the upcoming earnings report as a key catalyst. Discussions center on the growing revenue from Recorlev and the potential of other products, alongside optimism surrounding the company's technology platforms and potential acquisitions. Investors are closely watching for updates on collaborations and XP-8121, with some anticipating a significant rise in share price.

e.l.f. Beauty, Inc. is a holding company, which engages in the provision of inclusive, accessible, clean, vegan and cruelty free cosmetics and skin care products. The company focuses on the e-commerce, national retailers and international business channels. Its brands include elf, elf skin, naturium, well people, and keys soulcare. The company was founded in 2004 and is headquartered in Oakland, CA.

e.l.f. Beauty Inc

e.l.f. Beauty is trending after a recent forecast disappointed some investors, leading to discussions about reduced full-year guidance and profitability. Despite the negative sentiment, some traders see this as a buying opportunity, referencing the stock's history of rebounding after similar drops. The community is actively debating the company's valuation, growth prospects, and the potential impact of tariffs.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as community members discuss its recent surge and potential as a privacy-focused alternative to Bitcoin. Some investors are taking profits from other cryptocurrencies like ETH and XRP to allocate to ZEC, while others are debating its actual utility and future price targets. Discussion includes ZEC's limited supply and potential to flip other cryptos.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Misses Revenue Estimates

MaxCyte (MXCT) delivered earnings and revenue surprises of -20.00% and -14.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)

Glancy Prongay & Murray LLP (GPM) announces its investigation of MaxCyte, Inc. (NASDAQ: MXCT) concerning the Company and its directors and officers possible violations of state laws. If you own...

MaxCyte Director Executes Stock Options and Sells

MaxCyte (MXCT) has released an update. MaxCyte Inc., a leader in cell-engineering, has reported that their Non-Executive Director, John Johnston, h...

MaxCyte Announces Broker Name Change Post-Merger

MaxCyte (MXCT) has released an update. MaxCyte Inc., a leader in cell-engineering platform technologies, has announced a change of its Nominated Ad...

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

Be Biopharma to use MaxCyte's Flow Electroporation technology and ExPERT platform within its Engineered B Cell Medicines programsROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc...

Commit To Buy MaxCyte At $2.50, Earn 6.7% Annualized Using Options

Investors considering a purchase of MaxCyte Inc (MXCT) shares, but cautious about paying the going market price of 4.26/share, might benefit from considering selling puts among the alternative...

MaxCyte price target lowered by $2 at BTIG, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

MaxCyte affirms FY24 guidance

MaxCyte reports Q4 EPS (5c), consensus (7c)

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.11	--	--	N/A
Q2 '25	-$0.10	-$0.12	-20.00%	MISSED
Q1 '25	-$0.10	-$0.10	3.47%	BEAT
Q4 '24	-$0.12	-$0.10	16.47%	BEAT
Q3 '24	-$0.12	-$0.11	8.33%	BEAT

MXCT
MaxCyte Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest MXCT News

MXCTMaxCyte Inc